Phase 1 part of combined Phase 1/2 study initiated as part of pandemic preparedness against highly pathogenic avian influenza (H5N1) virus, considered to be potential future pandemic threat Study will assess monovalent vaccine candidate, encoding an influenza A H5-antigen using proprietary second-generation mRNA backbone Avian influenza is latest program progressing to clinical trials under bro...
Mr. Ramanayake brings more than fifteen years of experience in biopharma company development and deal-making Strong track record of successful clinical collaborations, M&A, asset in-licensing and strategic financing initiatives across multiple therapeutic areas TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / April 24, 2024 / CureVac N.V. (Nasdaq:CVAC) ("CureVac"), a global biopharmaceutical com...
Diese Pressemitteilung enthält Aussagen, die „zukunftsgerichtete Aussagen“ im Sinne des United States Private Securities Litigation Reform Act von 1995 darstellen, einschließlich Aussagen, die Meinungen, Erwartungen, Überzeugungen, Pläne, Ziele, Annahmen oder Prognosen der CureVac N.V. und/oder i...
Diese Pressemitteilung enthält Aussagen, die „zukunftsgerichtete Aussagen“ im Sinne des United States Private Securities Litigation Reform Act von 1995 darstellen, einschließlich Aussagen, die Meinungen, Erwartungen, Überzeugungen, Pläne, Ziele, Annahmen oder Prognosen der CureVac N.V. und/oder i...
Diese Pressemitteilung enthält Aussagen, die „zukunftsgerichtete Aussagen“ im Sinne des United States Private Securities Litigation Reform Act von 1995 darstellen, einschließlich Aussagen, die Meinungen, Erwartungen, Überzeugungen, Pläne, Ziele, Annahmen oder Prognosen der CureVac N.V. und/oder i...
TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / April 18, 2024 / CureVac N.V. (Nasdaq:CVAC) ("CureVac"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), will report financial results, and provide business updates for the fourth quarter and full-year 2023 on Wednesday, April 24, 2024.
Diese Pressemitteilung enthält Aussagen, die „zukunftsgerichtete Aussagen“ im Sinne des United States Private Securities Litigation Reform Act von 1995 darstellen, einschließlich Aussagen, die Meinungen, Erwartungen, Überzeugungen, Pläne, Ziele, Annahmen oder Prognosen der CureVac N.V. und/oder i...
Agreement creates strong synergies between CureVac's unique end-to-end mRNA capabilities and MD Anderson's translational and clinical research expertise Collaboration aims to develop novel, off-the-shelf, mRNA-based cancer vaccines in selected hematological and solid cancers with high unmet medical need MD Anderson responsible for leading initial Phase 1/2 studies; CureVac retains worldwide exc...
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.